Abilify MyCite (aripiprazole tablet with sensor) — Point32Health

Initial criteria

• Patient age ≥ 18 years
• Diagnosis of bipolar disorder, schizophrenia, or major depressive disorder
• History of poor adherence (<80%) with at least two oral second generation antipsychotics, one of which must be aripiprazole
• Treatment failure or intolerance to long-acting injectable aripiprazole, or rationale that LAI aripiprazole is not medically appropriate
• Low medication adherence rate not due to inadequate response, intolerance, or adverse effect
• Patient experienced worsening symptoms due to poor adherence
• Patient has attempted all of the following adherence strategies: use of pillboxes, setting reminder alarms, coordinating administration with other daily medications
• Comprehensive treatment plan including use of the mobile app/web-based portal to monitor treatment